Michael Dilworth Receives IAM Strategy 300 Recognition
Jan 21st, 2021 by Dilworth IP | News | Recent News & Articles |
Michael Dilworth, our founder, was featured on the “IAM Strategy 300” Global Leaders Guide, as a leading figure in the IP world.
Jan 21st, 2021 by Dilworth IP | News | Recent News & Articles | Share
Michael Dilworth, our founder, was featured on the “IAM Strategy 300” Global Leaders Guide, as a leading figure in the IP world.
Jan 7th, 2021 by Michael Dilworth | News | Recent News & Articles | Share
IP protection includes patents to prevent theft of original concepts, trademarks to safeguard brand identify, copyrights to protect literary and artistic works, and trade secrets to preserve the secrecy of confidential information that gives your business a competitive edge.
Jan 5th, 2021 by Michael Dilworth | News | Recent News & Articles | Share
IP assets are a powerful resource for driving revenue growth and stronger returns on the company’s innovation investments. Learn how in this article on leveraging the power of IP.
May 29th, 2019 by Thomas Pia | Announcements | News | Share
Dilworth IP is very excited to announce that our new website, launched earlier this year to more accurately represent the culture and values of our firm, has been chosen from over 200,000 entries as a Platinum Winner of the prestigious Hermes Award—an honor awarded to only 1% of applicants. The Hermes Creative Awards is an international competition that is administered and judged by the Association of Marketing and Communication Professionals (AMCP), and recognizes excellence in the concept and design of marketing programs. Entries are submitted from a wide array of industries, and are judged at random on a point system according to their particular merits rather than directly compared to other entries
May 28th, 2019 by William Reid | News | Patent Related Court Rulings | Share
The ‘209 Patent includes method claims where folic acid and a methylmalonic acid lowering agent (e.g., vitamin B12) are administered prior to treatment with the antifolate pemetrexed disodium, a chemotherapy agent.[3] The folic acid and methylmalonic acid are used to ameliorate the toxic effects of the pemetrexed.[4] The heart of the Board’s conclusion was that although it was known to use folic acid to reduce the toxicity of antifolates such as pemetrexed, there was no reason to pretreat with vitamin B12 and folic acid prior to treatment with pemetrexed for cancer.[5] On appeal, the Petitioner’s obviousness arguments related to the EP005 reference, which taught use of folic acid in conjunction with vitamin B12 to reduce homocysteine levels for all purposes.[6] Homocysteine is an amino acid, and when present in high levels is predictive of pemetrexed toxicity.[7] On its face this appears to be a solid case for obviousness. Indeed, those arguing against motivation to combine during patent prosecution have almost certainly encountered an Examiner’s response referencing MPEP 2144IV at one time or the other:
May 9th, 2019 by Ben Lehberger | News | Recent News & Articles | Share
Trade secret law provides protection for information that its owner takes reasonable measures to keep secret and that derives independent economic value from not being generally known or readily ascertainable. If a trade secret is misappropriated by another, the owner may be entitled to damages, an injunction preventing further use or disclosure of the trade secret, and in some cases the recovery of attorneys’ fees.
May 7th, 2019 by William Reid | News | Patent Related Court Rulings | Recent News & Articles | Share
In Endo Pharmaceuticals Inc. v. Teva[1] the Federal Circuit has further clarified the patent eligibility of treatment methods which include natural elements. The Opinion, which includes comparisons with other cases such as Vanda[2], CellzDirect[3] and Ariosa Diagnostics[4], leaves one crafting such claims on ground that is fairly firm.
Apr 9th, 2019 by William Reid | News | Patent Related Court Rulings | Patent Trends & Activity | Share
There is a scene in the Big Lebowski where the Dude complains about the lousy day he just had as he tosses down some snacks at a bowling alley bar. In answer, the Stranger (played by Sam Elliot) offers the above advice as to the Dude’s existential situation. It didn’t help. One can almost imagine a similar response from Apple following the Federal Circuit’s decision in Personal Web Technologies, LLC, v. Apple, Inc., 2018-1599 (Fed. Cir. March 8, 2019), since it marked the second time in two years they had won at the Board, only to be disappointed at the Federal Circuit on the same patent, PWT’s 7,802,310 (‘310 Patent)[1]. While the Federal Circuit’s analysis in both cases was nominally different, the underlying theme in both was the need for a proper motivation-to-combine analysis.
Mar 19th, 2019 by William Reid | News | Patent Related Court Rulings | Patent Trends & Activity | Share
Lead compound analysis (LCA) has been used in the evaluation of chemical compound Obviousness for the past 20 years.[1] This approach supplemented the historic formulation of In re Dillon.[2] While the Dillon analysis pivots about the structural similarity of the cited compound to that claimed and any motivation to make the claimed compound, LCA involves selection of a lead compound that is the most promising candidate for modification to improve its activity. As such, it represents a somewhat more difficult standard than in Dillon.
Mar 14th, 2019 by Thomas Pia | Announcements | News | Share
Dilworth IP’s Benjamin Lehberger recently spoke at the Lawyer-Pilot Bar Association’s Winter 2019 Convention in Cocoa Beach, FL. Ben’s talk, entitled “Where are We Headed in Space? Charting the Industry’s Trajectory Through Patent Filings” showed how the patent landscape for space technology has changed dramatically over time. Despite NASA being the dominant filer for decades, Ben showed that the last 20 years of filings have been led by private firms. He also considered how the latest patents filings, on technologies such as artificial gravity and global internet access, give insight into what’s next in space.